Systematic review on drug and diet-induced endoscopic remission in Crohn's disease

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 5, 2009, Pages 491-503

  Pimentel Nunes, Pedro ^a   Dinis Ribeiro, Mario ^a   Magro, Fernando ^b,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Crohn's disease; Crohn's disease therapy; Endoscopic remission; Mucosal healing

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; FONTOLIZUMAB; IMMUNOMODULATING AGENT; INFLIXIMAB; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE; STEROID;

ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DIET THERAPY; GASTROINTESTINAL ENDOSCOPY; HUMAN; INTERMETHOD COMPARISON; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SYSTEMATIC REVIEW;

CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; HUMANS; PROGNOSIS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 67651172838     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283196b03     Document Type: Article

References (45)

1. Wells RW, Blennerhassett MG. The increasing prevalence of Crohn's disease in industrialized societies: the price of progress? Can J Gastroenterol 2005; 19:89-95.
2. Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1998; 114:1161-1168.
3. Munkholm P, Langholz E, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-1987: a sixfold increase in incidence. Scand J Gastroenterol 1992; 27:609-614.
4. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:182-205. (Pubitemid 28307304)
5. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996; 23:29-34. (Pubitemid 26244497)
6. Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 2003; 17 (Suppl 2):11-17. (Pubitemid 36831453)
7. Ekbom A, Helmick C, Zack M, Adami HO. The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology 1991; 100:350-358.
8. Munkholm P. Crohn's disease-occurrence, course and prognosis. An epidemiologic cohort-study. Dan Med Bull 1997; 44:287-302.
9. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, Modigliani R, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122:512-530. (Pubitemid 34117002)
10. Vermeire S, van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn's disease-evidence for and against current therapies. Aliment Pharmacol Ther 2007; 25:3-12. (Pubitemid 44902859)
11. Landi B, Anh TN, Cortot A, Soule JC, Rene E, Gendre JP, et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The groupe d'etudes therapeutiques des affections inflammatoires digestives. Gastroenterology 1992;102:1647-1653.
12. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes therapeutiques des affections inflammatoires du tube digestif (GETAID). Gut 1989; 30:983-989.
13. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63:433-442. (Pubitemid 43261469)
14. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357:1191-1194. (Pubitemid 32378696)
15. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370:1453-1457.
16. Olaison G, Sjodahl R, Tagesson C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 1990; 31:325-328. (Pubitemid 20093672)
17. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, Rene E. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude therapeutique des affections inflammatoires digestives. Gastroenterology 1990; 98:811-818.
18. Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006; 4:744-753. (Pubitemid 43825808)
19. Berni Canani R, Terrin G, Borrelli O, Romano MT, Manguso F, Coruzzo A, et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig Liver Dis 2006; 38:381-387. (Pubitemid 44356207)
20. Van Dullemen HM, Van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN,Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109:129-135.
21. D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116:1029-1034. (Pubitemid 29203012)
22. Asakura H, Yao T, Matsui T, Koganei K, Fukushima T, Takazoe M, et al. Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings. J Gastroenterol Hepatol 2001; 16:763-769. (Pubitemid 34188813)
23. Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003; 98:833-838. (Pubitemid 36576310)
24. Gheorghe L, Gheorghe C, Badea M, Vadan R, Parvulescu I, Toader C, et al. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania. Rom J Gastroenterol 2003; 12:7-13. (Pubitemid 36433036)
25. Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004; 36:342-347. (Pubitemid 41115465)
26. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126:402-413. (Pubitemid 38182297)
27. Rigaud D, Cosnes J, Le Quintrec Y, Rene E, Gendre JP, Mignon M. Controlled trial comparing two types of enteral nutrition in treatment of active Crohn's disease: elemental versus polymeric diet. Gut 1991; 32:1492-1497.
28. Beattie RM, Schiffrin EJ, Donnet-Hughes A, Huggett AC, Domizio P, MacDonald TT, Walker-Smith JA. Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease. Aliment Pharmacol Ther 1994; 8:609-615. (Pubitemid 24381361)
29. Fell JM, Paintin M, Arnaud-Battandier F, Beattie RM, Hollis A, Kitching P, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000; 14:281-289. (Pubitemid 30145315)
30. Afzal NA, Van Der Zaag-Loonen HJ, Arnaud-Battandier F, Davies S, Murch S, Derkx B, et al. Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther 2004; 20:167-172. (Pubitemid 38998214)
31. Yamamoto T, Nakahigashi M, Umegae S, Kitagawa T, Matsumoto K. Impact of elemental diet on mucosal inflammation in patients with active Crohn's disease: cytokine production and endoscopic and histological findings. Inflamm Bowel Dis 2005; 11:580-588. (Pubitemid 40826346)
32. Sandborn WJ, Van OE, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995; 109:1808-1817.
33. D'Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997; 112:1475-1481. (Pubitemid 27181370)
34. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999; 50:667-671. (Pubitemid 29518050)
35. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110:353-356.
36. Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 1997; 40:470-474. (Pubitemid 27204925)
37. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The interleukin 10 inflammatory bowel disease cooperative study group. Gastroenterology 2000; 119:1473-1482. (Pubitemid 32198672)
38. Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 2006; 55:1138-1144. (Pubitemid 44085682)
39. Froslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133:412-422. (Pubitemid 47187355)
40. Lowenberg M, Peppelenbosch M, Hommes D. Biological therapy in the management of recent-onset Crohn's disease: why, when and how? Drugs 2006; 66:1431-1439. (Pubitemid 44246602)
41. Oldenburg B, Hommes D. Biological therapies in inflammatory bowel disease: top-down or bottom-up? Current opinion in gastroenterology 2007; 23:395-399.
42. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119:15-22. (Pubitemid 30452574)
43. Wyatt J, Vogelsang H, Hubl W,Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993; 341:1437-1439. (Pubitemid 23161445)
44. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99:956-963. (Pubitemid 20338451)
45. Griffiths AM. Enteral feeding in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 2006; 9:314-318. (Pubitemid 44097846)